MacroGenics shares surge 19.26% intraday on breakthrough results and CEO's conference presentation.

MacroGenics surged 19.26% intraday, driven by insider buying and positive developments in its cancer therapeutics pipeline. The stock’s rally followed a 909% increase in shares held by Independent Chairman William Heiden, who purchased $151,000 of shares at $1.52, close to the current price, signaling confidence in the company’s outlook. Additionally, investor sentiment was bolstered by promising breakthrough results in antibody-based treatments, highlighted by CEO Eric Risser’s upcoming presentation at the Evercore Healthcare Conference, which underscored potential growth in oncology innovations. These factors combined to fuel intraday buying momentum, reflecting optimism about MacroGenics’ strategic direction and therapeutic advancements.